nach oben

Erschienen in:

05.01.2022 | Original Article

Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis

verfasst von: Takanori Miyoshi, Toshinobu Hayashi, Miyuki Uoi, Fuyuki Omura, Kyouichi Tsumagari, Sachi Maesaki, Chiaki Yokota, Takafumi Nakano, Takashi Egawa

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The protective effect of magnesium (Mg) supplementation against cisplatin (CDDP)-induced nephrotoxicity has been widely described; however, the optimal dose of Mg supplementation is unclear. The aim of this study was to investigate whether 20 mEq of Mg supplementation is more effective than 8 mEq Mg in preventing CDDP-induced nephrotoxicity, as well as the associated risk factors, in cancer patients treated with CDDP-based chemotherapy.

Methods

Pooled data of 272 patients receiving 20 mEq or 8 mEq Mg supplementation to CDDP-based chemotherapy from a multicenter, retrospective, observational study were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify the risk factors for renal failure induced by each treatment dose.

Results

There was no significant difference in the incidence of nephrotoxicity between the 8 mEq and 20 mEq groups (P = 0.926). There was also no significant difference in the severity of nephrotoxicity, elevated serum creatinine levels, and decreased estimated creatinine clearance levels between the two groups. Cardiac disease and albumin levels were identified as independent risk factors for CDDP-induced nephrotoxicity.

Conclusion

We did not find an advantage of 20 mEq over 8 mEq Mg supplementation in terms of a preventive effect against CDDP-induced nephrotoxicity. The optimal dose of Mg supplementation for the prevention of CDDP-induced nephrotoxicity remains unknown, and further studies are warranted.

Nur mit Berechtigung zugänglich

Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889–901. https://doi.org/10.1517/14656566.4.6.889CrossRefPubMed

Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441–445. https://doi.org/10.1080/08880010590964381CrossRefPubMed

Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368–379. https://doi.org/10.1016/s0272-6386(86)80112-3CrossRefPubMed

Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations J Pharmacol Exp Ther 213:551–556PubMed

Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmès P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35:1–9. https://doi.org/10.1007/BF00686277CrossRefPubMed

Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147–158. https://doi.org/10.1006/gyno.1993.1184CrossRefPubMed

Sobrero A, Guglielmi A, Aschele C, Rosso R (1990) Current strategies to reduce cisplatin toxicity. J Chemother 2:3–7. https://doi.org/10.1080/1120009x.1990.11738971CrossRefPubMed

Finley RS, Fortner CL, Grove WR (1985) Cisplatin nephrotoxicity: a summary of preventative interventions. Drug Intell Clin Pharm 19:362–367. https://doi.org/10.1177/106002808501900505CrossRefPubMed

Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25:47–58. https://doi.org/10.1053/ctrv.1999.0097CrossRefPubMed

10.

Vickers AEM, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P (2004) Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32:577–590. https://doi.org/10.1080/01926230490508821CrossRefPubMed

11.

Alves SC, Tomasi CD, Constantino L, Giombelli V, Candal R, Bristot Mde L, Topanotti MF, Burdmann EA, Dal-Pizzol F, Fraga CM, Ritter C (2013) Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 28:910–916. https://doi.org/10.1093/ndt/gfs268CrossRefPubMed

12.

Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608–2614. https://doi.org/10.1016/j.ejca.2008.08.005CrossRefPubMed

13.

Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54:19–23. https://doi.org/10.1038/bjc.1986.147CrossRefPubMedPubMedCentral

14.

Martin M, Diaz-Rubio E, Casado A, López Vega JM, Sastre J, Almenarez J (1992) Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 15:348–351. https://doi.org/10.1097/00000421-199208000-00016CrossRefPubMed

15.

Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y (2014) Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. Jpn J Clin Oncol 44:346–354. https://doi.org/10.1093/jjco/hyu004CrossRefPubMed

16.

Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama lung cancer study group Trial 1002. Jpn J Clin Oncol 43:1115–1123. https://doi.org/10.1093/jjco/hyt128CrossRefPubMed

17.

Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T (2013) Short hydration in chemotherapy containing cisplatin (>=75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43:1105–1109. https://doi.org/10.1093/jjco/hyt122CrossRefPubMed

18.

Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S-I, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE 9:e101902. https://doi.org/10.1371/journal.pone.0101902CrossRefPubMedPubMedCentral

19.

Hase T, Miyazaki M, Ichikawa K, Yogo N, Ozawa N, Hatta T, Ando M, Sato M, Kondo M, Yamada K, Hasegawa Y (2020) Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study. Int J Clin Oncol 25:1928–1935. https://doi.org/10.1007/s10147-020-01755-1CrossRefPubMed

20.

Miyoshi T, Uoi M, Omura F, Tsumagari K, Maesaki S, Yokota C (2021) Risk factors for cisplatin-induced nephrotoxicity: a multicenter retrospective study. Oncology 99:105–113. https://doi.org/10.1159/00051038421CrossRefPubMed

21.

Haim N, Oman SD, Galai N, Burde B, Nathan S, Catane R (1993) Estimation of creatinine clearance without 24-hour urine collection—a useful guide during cisplatin therapy. Acta oncol 32:409–412. https://doi.org/10.3109/02841869309093618CrossRefPubMed

22.

Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC (2018) Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol 36:682–688. https://doi.org/10.1200/JCO.2017.75.7161CrossRefPubMedPubMedCentral

23.

Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E, Noda Y (2013) The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85:364–369. https://doi.org/10.1159/000356587CrossRefPubMed

24.

Saito Y, Kobayashi M, Yamada T, Kasashi K, Honma R, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K (2017) Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer 25:481–487. https://doi.org/10.1007/s00520-016-3426-5CrossRefPubMed

25.

Tong GM, Rude RK (2005) Magnesium deficiency in critical illness. J Intensive Care Med 20:3–17. https://doi.org/10.1177/0885066604271539CrossRefPubMed

26.

Horiuchi M, Inuyama Y, Kohno N, Mashino S, Fujii M (1982) Pharmacokinetics of cis-dichlorodiammineplatinum (II). Gan To Kagaku Ryoho 9:632–637PubMed

27.

Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131–137. https://doi.org/10.1007/s002800050548CrossRefPubMed

28.

Nagai N, Ogata H (1997) Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40:11–18. https://doi.org/10.1007/s002800050618CrossRefPubMed

29.

Teramachi H, Hatakeyama H, Matsushita R, Imai Y, Miyamoto KI, Tsuji A (2002) Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol Pharm Bull 25:1333–1338. https://doi.org/10.1248/bpb.25.1333CrossRefPubMed

Titel: Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis
verfasst von: Takanori Miyoshi
Toshinobu Hayashi
Miyuki Uoi
Fuyuki Omura
Kyouichi Tsumagari
Sachi Maesaki
Chiaki Yokota
Takafumi Nakano
Takashi Egawa
Publikationsdatum: 05.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06790-w

The preventive effects of perioperative oral care on surgical site infections after pancreatic cancer surgery: a retrospective study

Original Article

Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India

Original Article

Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis

Review Article

Cross-sectional analysis of myosteatosis and physical function in pretreatment head and neck cancer patients

Original Article

Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study

Open Access
Original Article

Early versus the traditional start of oral intake following esophagectomy for esophageal cancer: a systematic review and meta-analysis

Original Article

Neu im Fachgebiet Onkologie

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

15.01.2025
Melanom
Nachrichten

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

15.01.2025
Akute myeloische Leukämie
Nachrichten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

14.01.2025
Nierenkarzinom
Nachrichten

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

14.01.2025
Prostatakarzinom
Nachrichten

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis